Associated Papers
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
41152984 (PubMed )
Supplement: 13073_2025_1564_MOESM2_ESM.xlsx › Table_S6
Insights into the role of JAK2-I724T variant in myeloproliferative neoplasms from a unique cohort of New Zealand patients.
Puli'uvea C et al.
Hematology (amsterdam, Netherlands), 2024
38197452 (PubMed )
Supplement: supplement_1.docx
Clinical forecasting of acute myeloid leukemia using ex vivo drug-sensitivity profiling.
Andersen AN et al.
Cell Reports Methods, 2023
38065095 (PubMed )
Supplement: mmc2.pdf
Structural Analysis of Janus Tyrosine Kinase Variants in Hematological Malignancies: Implications for Drug Development and Opportunities for Novel Therapeutic Strategies.
Rodriguez Moncivais OJ et al.
International Journal of Molecular Sciences, 2023
Molecular basis of JAK2 H608Y and H608N mutations in the pathology of acute myeloid leukemia.
Li F et al.
International Journal of Biological Macromolecules, 2023
Apparent 'JAK2-negative' polycythaemia vera due to compound mutations in exon 14.
Tiong IS et al.
British Journal of Haematology, 2017
Highly Concordant Key Genetic Alterations in Primary Tumors and Matched Distant Metastases in Differentiated Thyroid Cancer.
Sohn SY et al.
Thyroid : Official Journal of the American Thyroid Association, 2016
Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies.
Jatiani SS et al.
Genes & Cancer, 2010
Select a paper to view details